Angiotech rated at outperform by RBC

RBC Capital Markets analyst Douglas Miehm rated Angiotech Pharmaceuticals Inc. at outperform, speculative risk, after the company reported its second-quarter results. Angiotech had adjusted earnings per share of $0.20 and revenues of $97.6 million. Management reiterated guidance for the year. A few products, including the Contour Thread could become meaningful contributors to the company's operations over the next year or two, according to the analyst. Shares of the Vancouver, B.C.-based medical technology company were down 38 cents, or 3.21%, at $11.47, on volume of 372,346 shares versus the three-month running average of 384,089 shares. (Nasdaq: ANPI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.